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Abstract 
 
Pump thrombosis occurs during destination therapy (DT) with HeartMate II, a 
continuous blood flow left ventricular assist device (St Jude, Pleasanton, CA, 
USA). With adherence to stringent post-operative and long-term anticoagulation a 
low incidence of pump thrombosis was initially reported during DT. The increased 
PT incidence during DT that was reported in early 2013 was attributed to lenient 
anticoagulation. A wide range of pump thrombosis incidence during DT is being 
reported since the return to stringent post-operative and long-term anticoagulation. 
We searched PubMed from January 2008 to February 2016 for reports of pump 
thrombosis during mechanical circulatory support with HeartMate II and focus on 
the incidence rate of pump thrombosis from DT approval by the Food and Drug 
Administration to present. Pump thrombosis which may have been initially 
underestimated continues to complicate DT with HeartMate II despite stringent 
post-operative and long-term anticoagulation. 
Keywords: pump thrombosis, destination therapy, HeartMate II, left ventricular 
assist device 
 
Introduction 
 
In contrast to initial experience with the HeartMate Extended Vented Electric (XVE; 
Thoratec, Pleasanton, CA), a pulsatile-flow (PF) left ventricular assist device 
(LVAD), long-term mechanical circulatory support (MCS) with HeartMate II, a 
continuous-flow (CF) LVAD (St Jude, Pleasanton, CA), is no longer limited by 
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device mechanical dysfunction [1, 2]. With textured interior surfaces, HeartMate 
XVE did not require anticoagulation and was nearly free of pump thrombosis. On 
the other hand, HeartMate II does require anticoagulation and has a risk of pump 
thrombosis [3-7].  
Destination therapy (DT) with Heart Mate II was approved by the FDA in 2009 [8]. 
Early DT experience with HeartMate II was associated with a low incidence rate of 
pump thrombosis [8-10]. However, three high volume DT centers experienced an 
abrupt increase in pump thrombosis incidence rate in early 2013 [11]. Nowadays, 
pump thrombosis incidence rate during DT appears to vary greatly from center to 
center [12-22]. Investigations of pump thrombosis during DT are overwhelmingly of 
retrospective nature [12-22]. We searched PubMed from January 2008 to 
February 2016 for reports of pump thrombosis during long-term MCS with 
HeartMate II and focus on the incidence rate of pump thrombosis from approval of 
HeartMate II for DT to the latest reports. 
Incidence of Pump Thrombosis during Destination Therapy with 
HeartMate II   
Early Experience 
The first report of HeartMate II pump thrombosis was published in 2007 [23]. Pump 
thrombosis occurred 2 months after implantation in a patient after warfarin had 
been discontinued due to gastro-intestinal bleed. Symptoms improved and power 
surges receded after intravenous administration of hirudin for 18 days. However, 3 
months later return of symptoms and power surges motivated rapid cardiac 
transplantation. A thrombus was found in the inflow cannula [23].  
A low incidence of pump thrombosis was reported in the trial that led to approval of 
HeartMate II for DT by the FDA [9]. Bleeding was by far the most prevalent 
adverse event as 108 of the 133 randomized patients to CF-LVAD (82%) required 
blood transfusion. Pump thrombosis occurred in 5 patients (4%). An even lower 
pump thrombosis incidence rate was noted in the 281 patients enrolled in the 
continuous access protocol approved by the FDA for evaluation of HeartMate II 
[22]. Only 4 of 281 patients (1.4%) experienced primary PT. In contrast, ischemic 
stroke outnumbered hemorrhagic stroke (11% versus 8%) in the extended access 
protocol [22]. As detailed later, no mention of PT is made in the third Interagency 
Registry of Mechanically Assisted Circulatory Support (INTERMACS) report of the 
outcome of patients who underwent long-term MCS from June 2006 through 
September 2010 [8].  
From 2006 to 2012 investigators have reported a PT incidence rate that was 
overall greater than that noted in the landmark HeartMate II trial. Reports from 
Park et al. and Hasin et al. reveal an increased incidence rate of pump thrombosis 
with HeartMate II from 4% in 2005-2007 to 6% in 2007-2009 with a peak of 9.3% 
during the period from 2008 to 2011 [24, 25]. 
Later Experience  
In late 2013 three high volume DT centers reported an abrupt increase in 
incidence rate of pump thrombosis from March 2011 and culminated in an 
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incidence rate of 7.5% and 12.4% after 12 and 24 months of support, respectively 
[11]. The center with the lowest incidence of pump thrombosis before March 2011 
had the greatest incidence after March 2011 [11]. The abrupt increase in pump 
thrombosis incidence rate was retrospectively attributed to a lenient 
anticoagulation regimen, to forfeiting the use of heparin post-operatively or to both 
[11]. Facing a high prevalence of bleeding in the post-operative period and during 
the long-term follow up, DT centers lowered the international normalized ratio 
(INR) target from 2-3 to 1.5 -2.5 and abandoned the post-operative use of heparin 
[10, 24]. Modifications of the initial CF-LVAD or in the anticoagulation protocol did 
not apparently result in an increased rate of pump thrombosis [10, 24].  Over the 
past 2-3 years DT single centers and registries have reported an extremely 
variable incidence rate of PT that ranged from 6 to 40% [12-22].  
At the University of Pennsylvania Medical Center, 16 of 90 patients (20%) who 
underwent HeartMate II implantation from January 2011 to March 2014 
experienced pump thrombosis which was visually confirmed upon device 
explantation [13]. From March 2006 to June 2014, 179 patients received a 
HeartMate II and 21 patients a Heartware at Yale University Medical Center. The 
indication was DT for 102 patients and BTT in 98 patients [14]. The overall 
incidence rate of pump thrombosis was 6% [14]. The incidence of pump 
thrombosis in patients with a HeartMate II for DT was not provided. The majority of 
pump thrombosis (83%) occurred from 2006 to 2012 with only 3 events over the 
past 2 years. The decreasing pump thrombosis incidence rate was attributed to 
implementation of a more aggressive anticoagulation regimen. Sixty four patients 
underwent first implantation of CF-LVAD at Tampa General Hospital (Tampa, FL) 
from October 2011 to October 2013 [15]. The CF-LVAD was HeartMate II in 56 
patients and Heartware in 8 patients. Pump thrombosis that was confirmed by 
visualization of the thrombus upon explant occurred in 12.5% of patients. 
Incidence rate of pump thrombosis was similar with HeartMate II and Heartware. 
Not all patients received antiplatelet therapy. A greater pump thrombosis incidence 
rate was noted in patients who did not receive antiplatelet therapy.  
Seven of the 18 patients (39%) who were implanted with HeartMate II for DT from 
January 2010 to December 2013 at our institution experienced pump thrombosis 
that was confirmed at disassembly of the device at Thoratec (Pleasantville CA) in 
6 patients [16]. All 18 patients received standard therapy post implant including 
antiplatelet therapy and warfarin. The INR target was increased from 2-3 to 2.5-3.5 
after the first pump thrombosis event. None of the patients were bridged with 
heparin post operatively.  
Preexisting inflammatory conditions and infectious complications were common in 
patients with pump thrombosis and rare in patients without pump thrombosis. A 
recent retrospective evaluation of 276 patients who underwent HeartMate II 
implantation for DT (N=176) or BTT (N=100) from April 2009 to September 2012 in 
27 centers, reported 4 device exchanges for pump thrombosis over an average 
MCS duration of 8.3 months [17]. Whether pump thrombosis occurred in DT or 
BTT patients is unclear. One-year survival of DT patients was 70% [17]. Five DT 
patients suffered an ischemic stroke.  
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Seven hundred and thirty four patients with first CF-LVAD implantation were 
enrolled in the Mechanical Circulatory Support Research Network Registry from 
May 2004 to September 2014 [21]. HeartMate II was implanted in 560 patients and 
Heartware was implanted in 174 patients. The cumulative risk of pump thrombosis 
was 14, 24 and 25 % at 1, 3 and 5 years, respectively. The incidence rate of pump 
thrombosis decreased from 36% before August 2011 to 7.5% after August 2011. A 
lower INTERMACS profile was the only independent predictor of PT. The type of 
CF-LVAD was not an independent predictor of pump thrombosis in the 
multivariable model.  The cumulative risk of ischemic stroke was 4, 9 and 10% at 
1, 3 and 5 years, respectively. Fifty-five patients underwent echocardiographic 
ramp testing after HeartMate II implantation at the University of Minnesota 
(Minneapolis, MN) [26]. Thirteen of the 55 patients (23.6%) experienced PT that 
was confirmed by visualization of device obstruction. The main findings of above 
mentioned single centers and registries are summarized in Figure 1.  
 
Figure 1 Incidence of pump thrombosis (PT) across studies of long-term 
mechanical circulatory support with HeartMate II left ventricular assist 
device. For each study, a mean of the study time period has been used as a 
time point to depict PT incidence. Studies with outlying PT incidence rates 
have been excluded [Samson et al [16] and Katz et al [17]. Abbreviations: 
AC: anticoagulation. 
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The Interagency Registry for Mechanically Assisted Circulatory Support Data 
The INTERMACS reports mention pump thrombosis as an adverse event when it 
results in a fatal outcome or when it requires pump exchange. The fifth 
INTERMACS annual report that analyzed patient enrollment and outcomes from 
June 23, 2006 till June 30, 2012 did not mention any pump thrombosis as adverse 
event during long-term MCS with CF-LVAD [2]. The report mentions 660 device 
malfunctions for 5,358 CF-LVAD implantations (12.3%). A similar rate of device 
malfunction (11.5%) without mention of pump thrombosis is noted in the following 
quarterly INTERMACS report implants. The issue of pump thrombosis was 
specifically addressed by INTERMACS in 2014 [3]. Freedom from device 
exchange or death due to pump thrombosis was reported to have decreased from 
99% at 6 months in 2009 to 94% in 2012. INTERMACS revisited the issue of pump 
thrombosis one year later [4]. The freedom from pump thrombosis at 6 months fell 
from 98% in 2010 to 92% in 2013 and subsequently improved to 95% through 
June 2014 [4]. Whether pump thrombosis occurrence effectively decreased is 
uncertain. A novel analysis of the complete all INTERMACS data using machine 
learning random forests survival methodology confirmed that the risk of pump 
thrombosis plateaued in 2013-early 2014 [6]. The novel analysis estimates the 
current risk for pump thrombosis at 10% that is greater than that initially reported 
[6]. 
Mechanistic insight  
Pump thrombosis is obviously a complex issue that may result from mechanical 
and non-mechanical factors [5, 7, 27-29]. As HeartMate II implantation becomes 
an increasingly performed procedure, cardiothoracic surgeons are fully familiar 
with correct implant techniques [30]. Inflow cannula misplacement, outflow graft 
malposition and pump pocket depth may only be responsible for few instances of 
pump thrombosis [13]. Recent modifications to the HeartMate II surfaces have 
apparently not affected the incidence rate of pump thrombosis that remained 
extremely variable.  
Non-mechanical potential causes of pump thrombosis have been extensively 
reviewed [5, 7, 27-29]. Uriel et al. drew attention to non-mechanical pump 
thrombosis that occurred in 14 of the 177 patients (8%) who underwent HeartMate 
II implantation at Columbia University Medical Center from January 1, 2009 to 
November 15, 2012 [12]. The pump thrombosis prevention protocol at Columbia 
included aspirin, warfarin with an INR target of 1.5 to 2.5 and dipyridamole in 
patients < 50 years old. An 11% incidence rate of pump thrombosis was reported 
by the Texas Heart Institute despite the use of an aggressive anticoagulation 
protocol in patients with HeartMate II implanted from April 2008 to June 2012 [31]. 
From January 2009 to June 2013 125 patients received a HeartMate II or a 
Heartware at Tufts Medical Center (Boston, MA) for BTT (N=81), DT (N=33) and 
bridge to decision (N=11) [18]. All patients received aspirin (325 mg) and warfarin 
with a target INR 2-3. During a median follow up of 270 days, pump thrombosis 
occurred in 21 of the 90 patients (23.3%) who received a HeartMate II. After 
adjusting for age, gender and BTT indication pump thrombosis incidence rate was 
similar with HeartMate II and Heartware [18]. In a prospective, multicenter 
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observational study of DT with HeartMate II that enrolled 97 patients, pump 
thrombosis incidence rate was 6% at 12 months albeit only 70% of patients 
received both warfarin and antiplatelet therapy post implantation [19].  
Two hundred and sixty four patients underwent HeartMate II implantation from 
January 2009 to June 2013 at the University of Washington School of Medicine (St 
Louis, MS) [20]. Hundred patients did not receive erythropoiesis stimulating agent, 
while and 121 received it. Pump thrombosis was confirmed by direct observation 
of an obstructive thrombus in the pump or suspected for severe hemolysis. Over a 
mean follow up period of 14.2 months, pump thrombosis incidence rate was 12% 
in patients not receiving erythropoiesis stimulating agent and 23% in patients 
receiving it [20].  
After the 2014 report of an abrupt PT increase and the return to aggressive 
anticoagulation the incidence rate of PT appears to vary greatly from center to 
center. Overall, many centers nowadays observe an incidence rate of PT ranging 
from 10 to 20% [12, 13, 15, 18, 20-22]. Thus, the return to an aggressive 
anticoagulation protocol has not been accompanied by a declining rate of pump 
thrombosis.   
An issue that has been less addressed is the underestimation of pump thrombosis 
in early reports of MCS with HeartMate II. Several oversights may have led to early 
underestimation of HeartMate II pump thrombosis. First, most centers which 
contributed to the approval of HeartMate II for DT by the FDA had previous 
experience with HeartMate XVE [9]. With uniquely textured surfaces HeartMate 
XVE was associated with an extremely low rate of PT during prolonged MCS. The 
physical examination adage “You find what you look for” may have led to pump 
thrombosis underestimation. Second, DT related implants increased from 28.5% in 
2011 to 44% in 2014 and BTT implants remained stable at 30%, the incidence rate 
of pump thrombosis seems to have increased with the longer duration of MCS 
associated with DT [32]. Third, pump thrombosis can masquerade as an arterial 
embolic event and particularly as ischemic stroke that is a not infrequently reported 
adverse event during long-term MCS with HeartMate II. Akin et al. reported such 
instance in a patient after HeartMate II implantation [33]. Finally, with HeartMate II 
being increasingly implanted for DT, patients may not have been as thoroughly 
screened for comorbid conditions that may contribute to pump thrombosis as are 
BTT patients. Malignancies, chronic inflammatory disorders, connective tissue 
diseases, autoimmune disorders and hypercoagulable states are known to 
increase the risk of thrombus formation [16].  
Treatment of suspected pump thrombosis is beyond the scope of the present 
review. However prevention/avoidance of PT is undoubtedly the undisputed goal 
of DT. Prevention of pump thrombosis requires long-term antiplatelet therapy with 
81-325 mg of aspirin and unremitting anticoagulation. Warfarin is the only available 
oral anticoagulant known to prevent formation of red clot within the device [7, 30]. 
A target INR of 2.5-3.5 may be preferable to that of 2-3 as recommended by 
current guidelines [34]. Temporary administration of fractionated heparin is 
recommended when INR is < 2. Plasma LDH level should be obtained with each 
INR determination. An unexplained abrupt increase in INR warrants computerized 
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tomography angiography/echocardiography ramp study and possibly thrombolytic 
therapy. 
Competitive and reversible inhibition of thrombin with dabigatran is not as effective 
as warfarin in suppressing mechanical heart valve thrombosis [35]. As probably 
occurs with mechanical heart valves, thrombin is generated in response to 
exposure of blood to the artificial surface of the CF-LVAD [7]. Unfortunately 
adherence to warfarin low with only 40.2% of patients with atrial fibrillation having 
warfarin readily available ≥ 80% of the time based on fill date and the days of 
supply on pharmacy claims [36]. Medication refill adherence is likely to 
underestimate warfarin non-adherence in patients with CF-LVAD who are closely 
monitored and unlikely to be left without warfarin prescriptions. Warfarin treatment 
in patients with CF-LVAD requires compulsive attention to time in the therapeutic 
range. Patient’s adherence to medications and diet is the key factor of pump 
thrombosis.  
Future Directions  
Early detection of pump thrombosis during HeartMate II support remains Achilles 
heel. Apart from inflammatory conditions and malignancies, recurrent sub-
therapeutic anticoagulation state and device related mechanical factors contribute 
to pump thrombosis (16). Regularly scheduled measurements of serum lactate 
dehydrogenase (LDH) levels appear more suitable for the detection of pump 
thrombosis than serial echocardiography. Serum LDH levels increase after 
HeartMate II implantation and thereafter tend to remain stable. Elevated LDH 
levels (>600U/L) have been noted in patients with clinical and echocardiographic 
evidence of pump thrombosis. However, absence of data on correlation between 
early rise in LDH level and thrombus formation makes early detection of pump 
thrombosis difficult. Review of confirmed cases of pump thrombosis may reveal 
relationship between the extent of increase in LDH level and the development of 
pump thrombosis. Furthermore, it is likely that we may not find “one-size-fit-for-all’ 
LDH level which should lead to the early detection of pump thrombosis. Instead, 
serial LDH level measurements may help establish a trend for a given patient and 
deviations should prompt further investigation. Knowing the increase in LDH levels 
should alert clinicians to pump thrombosis “in progress” and may allow early use of 
fractionated heparin to stop/slow the thrombus propagation.  
Meanwhile, the design of HeartMate 3 ((St Jude, Pleasanton, CA, USA) aimed at 
improving its hemocompatibility over that of previous devices by incorporating a 
magnetically levitated rotor with wide blood-flows paths and an artificial pulse. The 
HeartMate 3 device still requires aggressive anticoagulation with intravenous 
heparin as soon a chest tube drainage allows (<50ml/h for 3 hours) and aspirin 
plus Coumadin as soon as the patient can take oral medications. The target 
international normalized ratio (INR) is 2-3. Preliminary European experience in 50 
patients enrolled at 10 centers indicates that mechanical circulatory support (MCS) 
with HeartMate 3 is not associated with device thrombosis at 6 months (37). The 
absence of the device thrombosis at 6 months after implantation of HeartMate 3 is 
extremely promising. However, it clearly needs to be confirmed in a larger cohort 
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on a longer MCS duration. The ongoing MOMENTUM3 trial will provide more 
definitive information. The enrollment is expected to end in the middle of 2016 
(38). 
Conclusion  
In summary, pump thrombosis has been and continues to remain a major adverse 
event during destination therapy. Pump thrombosis may have been initially 
underestimated. Aggressive monitoring of anticoagulation and hemolysis is the 
sine qua non of pump thrombosis prevention. 
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